Last reviewed · How we verify
NCT07527611: CCBR
Development of a Conservative Care and Bracing Registry (CCBR)
trial in Adolescent Idiopathic Scoliosis (AIS) in 280 participants. Completed in 1 November 2025.
1 November 2025
Quick facts
| Lead sponsor | National Scoliosis Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 280 |
| Start date | 30 June 2024 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across United States |
Conditions studied
- Adolescent Idiopathic Scoliosis (AIS) — all drugs for Adolescent Idiopathic Scoliosis (AIS) →
- Ealy Onset Scoliosis — all drugs for Ealy Onset Scoliosis →
- Juvenile Idiopathic Scoliosis — all drugs for Juvenile Idiopathic Scoliosis →
- Infantile Idiopathic Scoliosis — all drugs for Infantile Idiopathic Scoliosis →
Sponsor
National Scoliosis Center
Who can join
Adults 1 to 18, any sex, with Adolescent Idiopathic Scoliosis (AIS) or Ealy Onset Scoliosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Idiopathic scoliosis (IS) is a common problem affecting approximately 3% of the population; its progression can lead to significant health problems. The BrAIST study proved brace effectiveness, which increased bracing interest and utilization globally. There is a lack of evidence-based guidelines for brace treatment. There is significant variability in the brace literature with little consistency in indications for brace treatment goals, brace types, use of monitors, timing of radiographs, and evaluation of skeletal maturity. This lack of evidence demonstrates a clear need for a multi-center brace registry. The first aim of this proposal is to develop a comprehensive retrospective brace registry. This project involves expert clinicians, researchers and an orthotist, each with broad clinical and research experience in the field of bracing for scoliosis. The retrospective registry will function as a pilot, providing strategies to optimize variables, streamline data collection and minimize missing data. The next step will be to develop and launch a multicenter, prospective brace registry and Quality Improvement registry.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07527611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adolescent Idiopathic Scoliosis (AIS)
Currently open trials in the same condition.
- NCT07379593 — Validation of the Clinical Decision Support Systems (CDSS) Developed in the EU Horizon PREPARE Project in the Rehabilita · NA · active not recruiting
- NCT06314594 — Personalized Prevention and Treatment Strategies for Adolescent Idiopathic Scoliosis Via a Comprehensive Health Manageme · NA · recruiting
- NCT06934278 — Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis · Phase 3 · recruiting
- NCT07045337 — Enhancing the Therapeutic Effect of Bracing for Adolescent Idiopathic Scoliosis With a Hybrid Bracing Protocol · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07527611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Scoliosis Center
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing